Cost-effectiveness of shared decision-making in determining challenge setting for nonsevere food protein-induced enterocolitis syndrome.

IF 5.8 2区 医学 Q1 ALLERGY Annals of Allergy Asthma & Immunology Pub Date : 2025-02-18 DOI:10.1016/j.anai.2025.01.022
Jason Sanders, Alexandra E Conway, Navya Kartha, Brinda Prasanna Kumar, John Oppenheimer, Marylee Verdi, Aikaterini Anagnostou, Elissa M Abrams, Karen S Hsu Blatman, Matthew Greenhawt, Marcus S Shaker
{"title":"Cost-effectiveness of shared decision-making in determining challenge setting for nonsevere food protein-induced enterocolitis syndrome.","authors":"Jason Sanders, Alexandra E Conway, Navya Kartha, Brinda Prasanna Kumar, John Oppenheimer, Marylee Verdi, Aikaterini Anagnostou, Elissa M Abrams, Karen S Hsu Blatman, Matthew Greenhawt, Marcus S Shaker","doi":"10.1016/j.anai.2025.01.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk of severe reactions. However, it is unclear whether the observed OFC is universally cost-effective in all contexts vs gradually titrated home OFCs when caregivers are willing to accept a risk-to-benefit tradeoff.</p><p><strong>Objective: </strong>To characterize the health and economic benefits of at-home vs supervised reintroduction OFC in patients with a history of mild-moderate index FPIES.</p><p><strong>Methods: </strong>Cohort analyses evaluated the cost-effectiveness of a gradually titrated home vs clinical or hospital OFC using population simulations (n = 200,000 patients) and simulations in a rural New England population (n = 105). Severe FPIES reactions were defined as necessitating intravenous fluids. Fatality rates were defined as occurring approximately in 1/1,000,000 FPIES OFCs. Motor vehicle fatality rates were applied based on the travel distance to the OFC site. The cost-effectiveness threshold was set at $10,000,000 per fatality prevented.</p><p><strong>Results: </strong>In the population simulation, the supervised OFC costs reached $411,088,445, with 18,680 severe reactions occurring (per-patient mean 0.093, SD 0.025), at a cost-per-fatality prevented of $124,233,328. In a simulation of a rural New England population with FPIES, the cost per severe reaction ranged from $11,790 to $46,304.</p><p><strong>Conclusion: </strong>A requirement for universally conducting FPIES challenges in an office-based or in-hospital setting is not cost-effective given extremely low FPIES reaction fatality rates, especially when compared with travel-based motor vehicle fatality rates. A shared decision-making approach may be appropriate to determine the challenge setting for patients with lower risk of severe reactions.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.anai.2025.01.022","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Food protein-induced enterocolitis syndrome (FPIES) affects approximately 0.5% of US children. Oral food challenges (OFCs) are frequently conducted to assess FPIES resolution in an observed setting, given the risk of severe reactions. However, it is unclear whether the observed OFC is universally cost-effective in all contexts vs gradually titrated home OFCs when caregivers are willing to accept a risk-to-benefit tradeoff.

Objective: To characterize the health and economic benefits of at-home vs supervised reintroduction OFC in patients with a history of mild-moderate index FPIES.

Methods: Cohort analyses evaluated the cost-effectiveness of a gradually titrated home vs clinical or hospital OFC using population simulations (n = 200,000 patients) and simulations in a rural New England population (n = 105). Severe FPIES reactions were defined as necessitating intravenous fluids. Fatality rates were defined as occurring approximately in 1/1,000,000 FPIES OFCs. Motor vehicle fatality rates were applied based on the travel distance to the OFC site. The cost-effectiveness threshold was set at $10,000,000 per fatality prevented.

Results: In the population simulation, the supervised OFC costs reached $411,088,445, with 18,680 severe reactions occurring (per-patient mean 0.093, SD 0.025), at a cost-per-fatality prevented of $124,233,328. In a simulation of a rural New England population with FPIES, the cost per severe reaction ranged from $11,790 to $46,304.

Conclusion: A requirement for universally conducting FPIES challenges in an office-based or in-hospital setting is not cost-effective given extremely low FPIES reaction fatality rates, especially when compared with travel-based motor vehicle fatality rates. A shared decision-making approach may be appropriate to determine the challenge setting for patients with lower risk of severe reactions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在确定非严重性食物蛋白诱发小肠结肠炎综合征的挑战设置时,共同决策的成本效益。
背景:食物蛋白诱发的小肠结肠炎综合征(FPIES)影响着约 0.5% 的美国儿童。考虑到严重反应的风险,口服食物挑战(OFC)经常在观察环境中进行,以评估 FPIES 的缓解情况。然而,当护理人员愿意接受风险与收益的权衡时,观察性口服食物挑战与逐步滴定的家庭口服食物挑战相比,是否在所有情况下都具有普遍的成本效益尚不清楚:目的:描述有轻度-中度指数FPIES病史的患者在家与在监护下重新使用OFC的健康和经济效益:队列分析采用人群模拟(n = 200,000 名患者)和新英格兰农村人群模拟(n = 105)评估了逐步滴定的家庭与临床或医院 OFC 的成本效益。严重 FPIES 反应定义为需要静脉输液。死亡率被定义为大约发生在 1/1,000,000 FPIES OFC 中。机动车死亡率是根据到 OFC 现场的行车距离计算的。成本效益阈值设定为每预防一起死亡事故 10,000,000 美元:在人口模拟中,监督的 OFC 成本达到 411,088,445 美元,发生了 18,680 起严重反应(每名患者平均 0.093,SD 0.025),每防止一起死亡事故的成本为 124,233,328 美元。在一项针对新英格兰农村地区 FPIES 患者的模拟研究中,每次严重反应的成本从 11,790 美元到 46,304 美元不等:鉴于 FPIES 反应致死率极低,尤其是与出行时的机动车致死率相比,要求在诊室或医院内普遍进行 FPIES 挑战并不划算。对于严重反应风险较低的患者,采用共同决策的方法来确定挑战环境可能是合适的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.50
自引率
6.80%
发文量
437
审稿时长
33 days
期刊介绍: Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.
期刊最新文献
Sleep Disruption in Chronic Rhinosinusitis Improves with Exhalation-Delivery Nasal Steroid Therapy. Ethical Considerations in Food Allergy Management: A Focus on Infants and Toddlers. Depression and anxiety in patients with atopic dermatitis: Recognizing and addressing mental health burden. Elevated oxidative stress and steroid insensitivity in patients with asthma and high body fat percentage. Increased asthma burden during and post the COVID-19 pandemic among U.S. adults.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1